8-K 1 s105083_8k.htm 8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): January 3, 2017

 

SECOND SIGHT MEDICAL PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
California
(State or Other Jurisdiction of Incorporation)

 

333-198073   02-0692322
(Commission File Number)   (IRS Employer Identification No.)

 

12744 San Fernando Road, Suite 400
Sylmar, California 91342

(Address of Principal Executive Offices)

 

(818) 833-5000
(Registrant's Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective after trading hours on January 3, 2017, Second Sight Medical Products, Inc. (the “Company”) granted options to certain employees and officers pursuant to the Second Sight Medical Products, Inc. 2011 Equity Incentive Plan. The following officers of the Company were awarded options:

 

Name  Title  Amount 
Robert Greenberg, M.D., Ph.D.  Chairman   256,410 
Will McGuire  President and Chief Executive Officer   571,330 
Thomas Miller  Chief Financial Officer   181,980 
Steve Okland  Commercial Vice President, U.S. and Canada   220,840 
Edward Randolph  Vice President of Manufacturing   151,170 
Gregoire Cosendai  Vice President of European Operations   228,190 

 

The options have a strike price of $1.97 per share, which was the closing price of Company’s shares on the effective date of grant. The options vest over a four year term of which one-fourth vests on the one year anniversary of the date of grant, with the remaining options vesting quarterly over three years thereafter.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 6, 2016

 

SECOND SIGHT MEDICAL PRODUCTS, INC.  
   
/s/ Thomas B. Miller  
By: Thomas B. Miller  
Chief Financial Officer  

 

 -2-